BD has obtained CE marking for the BD MAX™ Vaginal Panel. The new IVD assay will provide laboratories and clinicians the ability to use a single test to detect microorganisms responsible for Bacterial Vaginosis (BV), Candidiasis (CA) and Trichomoniasis (TV), which are the most common infectious causes of vaginitis.

"The BD MAX Vaginal Panel provides an objective and accurate solution to this incredibly common health issue. This is an important advancement because using traditional methods to detect the responsible microorganisms can be challenging, due to the presence of many interfering substances in specimens, the large number of mixed infections which occur and the subjectivity of these methods, which can lead to inconsistent interpretation of test results,” said Dr. Patrick Murray, worldwide senior director of scientific affairs for BD Life Sciences – Diagnostic Systems. “The BD MAX Vaginal Panel has the potential to help clinicians improve patient management and help laboratories increase workflow efficiency.”

The BD MAX™ System offers an efficient path to improved outcomes by combining and automating real-time PCR extraction, amplification and detection into a single platform capable of running both FDA-cleared and open-system assays.

For more information on BD Molecular Diagnostics, please visit: http://moleculardiagnostics.bd.com